Navigation Links
Intarcia Presents Compelling 48-week Results for ITCA 650 - Data Underlines the Promise to Become the First Injection-free GLP-1 Therapy at the 47th Annual EASD Meeting in Lisbon
Date:9/14/2011

se arms.

ITCA 650 dose weeks 13-48

20 mcg/day

40 mcg/day

60 mcg/day

80 mcg/dayMean baseline HbA1c (%)

7.8

7.8

8.1

7.9Mean week 48 HbA1c (%)

6.8

6.8

6.6

6.5Mean HbA1c change at week 48 (%)

-1.0

-1.0

-1.5

-1.4Mean weight change at week 48 (lbs)

-6.0

-10.8

-7.7

-7.9Based on the robust treatment response observed at the week-24 study endpoint and the durability of response observed at week 48, a starting dose of ITCA 650 20 mcg/day for weeks 1-12 followed by transition to ITCA 650 60 mcg/day appears to provide the greatest incremental reductions in HbA1c, FPG and body weight with the most favorable tolerability profile.

Throughout the extended treatment duration of the study, there were no treatment discontinuations due to nausea.  Numeric improvements were observed in measures of blood pressure and lipids at weeks 24 and 48 compared to baseline.

"Testing novel therapies over longer treatment durations is very important to confirm sustained effects, safety and tolerability," said Julio Rosenstock, MD, ITCA 650 phase 2 study principal investigator.  "These encouraging findings warrant further investigation of the optimized dose regimen of ITCA 650 20 to 60 mcg/day in larger phase 3 studies and using longer duration devices."  

Patient Satisfaction with ITCA 650 TherapyIn a separate session focusing on new GLP-1 therapies, Thomas R. Alessi, PhD, Intarcia's Vice President, Development, presented the results of a treatment satisfaction survey that was administered to patients before the beginning of the ITCA 650 phase 2 clinical study and at study weeks 8 and 20.  The survey utilized the Diabetes Medication Satisfaction Tool (DM-SAT), a validated and published self-assessment tool.  Study results indicated that patients receiving ITCA 650 at doses of either 20 mcg/day or 40
'/>"/>

SOURCE Intarcia Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes
2. Intarcia Therapeutics Names Kurt Graves Executive Chairman to Advance Strategic Interests and Broaden Commercial Goals
3. Intarcia Presents Positive ITCA 650 Phase 2 Study Results for Type 2 Diabetes at EASD
4. Intarcia Therapeutics Executive Chairman Kurt Graves to Present at 29th Annual JP Morgan Healthcare Conference
5. Intarcia Announces Presentations of Three Clinical Abstracts at the 47th Annual Meeting of the European Association for the Study of Diabetes
6. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
7. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
8. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
9. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
10. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... -- More than half of women diagnosed with early ... still have excellent outcomes. To educate women, Agendia, Inc. ... sources of online consumer information about breast cancer genomic ... recently diagnosed women with information sources, to help them ... "We anticipate these innovative social media campaigns will encourage ...
(Date:5/23/2013)... MONICA, Calif. , May 23, 2013 ... a program that would have required them to obtain ... today by Consumer Watchdog and Whatley Kallas LLC.  ... Diego Superior Court, alleged that Blue Cross,s mandatory mail ... patients, threatening their health and privacy. "This ...
(Date:5/23/2013)... 2013  Texas, premier physician associations today announced the ... tools they need to provide demonstrably better and more ... marketplace. "I am confident the Physician Services ... Stephen L. Brotherton , MD, president ... doctors are determined to make health care ...
Breaking Medicine Technology:Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 2Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 3Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 2Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 3TMA Launches Physician Services Organization for Patient Care 2TMA Launches Physician Services Organization for Patient Care 3TMA Launches Physician Services Organization for Patient Care 4
... 2011  Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today ... edoxaban, a direct oral once-daily Factor Xa inhibitor, significantly ... total knee or hip arthroplasty, when compared to enoxaparin. ... composite of deep vein thrombosis (DVT) and pulmonary embolism ...
... SHANGHAI, Dec. 12, 2011 /PRNewswire-Asia/ -- WuXi PharmaTech (NYSE: ... medical-device research and development outsourcing company with operations in ... of its fifth Life Science and Chemistry Awards, held ... Beijing. The theme of this year,s awards ...
Cached Medicine Technology:Edoxaban Significantly Reduces Risk of Venous Thromboembolism by Half Compared to Enoxaparin in Japanese and Taiwanese Patients Following Knee or Hip Arthroplasty Surgery 2Edoxaban Significantly Reduces Risk of Venous Thromboembolism by Half Compared to Enoxaparin in Japanese and Taiwanese Patients Following Knee or Hip Arthroplasty Surgery 3Edoxaban Significantly Reduces Risk of Venous Thromboembolism by Half Compared to Enoxaparin in Japanese and Taiwanese Patients Following Knee or Hip Arthroplasty Surgery 4Edoxaban Significantly Reduces Risk of Venous Thromboembolism by Half Compared to Enoxaparin in Japanese and Taiwanese Patients Following Knee or Hip Arthroplasty Surgery 5WuXi PharmaTech Presents the 2011 Life Science and Chemistry Awards 2WuXi PharmaTech Presents the 2011 Life Science and Chemistry Awards 3
(Date:5/24/2013)... Electric™ Energy Straws, an exciting new brand of ... and will be the lead sponsor on Munoz’s Chevy #26 ... Speedway. Munoz, who is part of Andretti Autosports’ fantastic five ... race, qualifying to be named the 2013 Indy 500 Fastest ... race. , While Munoz is grabbing headlines around the ...
(Date:5/24/2013)... The point-of-care (POC) diagnostics market encompasses ... central laboratory, by other healthcare professionals, patient self-testers ... consumers. This includes products that test blood glucose ... cardiovascular disease and cancer, as well as hospital ... and emergency departments. , Critical analysis and 5-year ...
(Date:5/24/2013)... is available in German . ... "alpha-synuclein" aggregates and accumulates within neurons. Specific areas of ... and advances. The mechanism underlying this pathological progression is ... protein (or abnormal forms of it) along nerve projections ... the German Center for Neurodegenerative Diseases (DZNE) in Bonn ...
(Date:5/24/2013)... York, NY (PRWEB) May 24, 2013 ... for the seventh commencement ceremony of American University ... Fisher Hall in Lincoln Center. , This was the ... master of ceremonies Dick Woodward, AUA’s Senior Vice President ... graduate processional and Dr. Reza Sanii, Associate Dean of ...
(Date:5/24/2013)... FRIDAY, May 24 (HealthDay News) -- Nearly three ... such as constipation and diarrhea, but these issues ... new study finds. Researchers from Loyola University ... bowel issues are due to physiological and hormonal ... women take during pregnancy also can play a ...
Breaking Medicine News(10 mins):Health News:Unistraw Electric™ Energy Straw Chevy Car Powers Indianapolis 500 Rookie Driver Carlos Munoz 2Health News:Unistraw Electric™ Energy Straw Chevy Car Powers Indianapolis 500 Rookie Driver Carlos Munoz 3Health News:Point of Care Diagnostics Market (POC) Analysis and 5 Year Forecast in New Research Report at ReportsnReports.com 2Health News:Point of Care Diagnostics Market (POC) Analysis and 5 Year Forecast in New Research Report at ReportsnReports.com 3Health News:Proteins in migration 2Health News:Proteins in migration 3Health News:Proteins in migration 4Health News:AUA Celebrates Seventh Annual Commencement Ceremony 2Health News:Bowel Issues Affect 3 Out of 4 Pregnant Women 2
... Your mother,s wrinkles or lack there of, ... age. In fact, a new study claims just the ... genetic make-up, certain environmental factors can add years to ... web-based version of Plastic and Reconstructive Surgery , ...
... geographic reach, expand access to patients - PRINCETON, ... CVD ), one of the world,s largest and most ... of three new clinical development offices in Kiev, Ukraine; ... the company,s global presence. Covance has been providing ...
... footage from Tucson, AZ, implicates a third Planned Parenthood ... video, UCLA student Lila Rose and her ... where Rose tells the nurse that Stollar, posing as ... nurse disregards the age difference and even cautions Stollar ...
... announces new updates to the NCCN Guidelines for ... Noteworthy additions include new recommendations on when to ... the use of PET/CT scanning for evaluative purposes, ... surgery. , FORT WASHINGTON, Pa., Feb. 3 ...
... 3 McKenna Long & Aldridge LLP (MLA) is ... of Defense for Homeland Defense, has joined the firm ... role, he will support the firm,s Life Sciences and ... Security and Disaster Planning, in addition to helping clients ...
... AMERIGROUP Corporation (NYSE: AGP ) announced today ... Chief Compliance Officer, a position charged with responsibility that ... and regulations. "John Finley,s valuable experience in government and ... out his duties at AMERIGROUP," said John E. Littel, ...
Cached Medicine News:Health News:Divorce, antidepressants, or weight gain/loss can add years to your face 2Health News:Covance Opens Three New Offices in Ukraine, Slovakia, and Israel 2Health News:Covance Opens Three New Offices in Ukraine, Slovakia, and Israel 3Health News:New Undercover Video Shows Tucson Planned Parenthood Hiding Rape of 15-Year-Old Girl 2Health News:NCCN Updates Breast Cancer and Breast Cancer Risk Reduction Guidelines 2Health News:NCCN Updates Breast Cancer and Breast Cancer Risk Reduction Guidelines 3Health News:NCCN Updates Breast Cancer and Breast Cancer Risk Reduction Guidelines 4Health News:Former Assistant Secretary of Defense for Homeland Defense Joins McKenna Long & Aldridge LLP 2Health News:AMERIGROUP Names Finley Chief Compliance Officer 2
Liberty Single Piece PMMA Lens with UV Absorber....
Optical implants for the replacement of the human crystalline lens in the visual correction of aphakia....
... a sterile nonpyrogenic, transparent viscoelastic solution of ... 12 mg/ml of high molecular weight (greater ... in physiological saline. In the limit of ... cps (105 Pa s) at 25 C ...
... Plus is the preferred viscoelastic for phacoemulsification ... reliably works from the start to the ... cohesive profile of this viscoelastic is the ... associated with phacoemulsification remove only a fraction ...
Medicine Products: